drugset / Trial / NCT00945191

Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer

NCT00945191

Phase 2 Completed 24 enrolled Daiichi Sankyo
NaSingle-groupOpen-labelTreatment

Summary

This trial assessed the effect of treatment with CS-1008 in combination with paclitaxel/carboplatin on response in patients with locally advanced or metastatic ovarian cancer.

Timeline

Start
2009-10-06
Primary completion
2011-08-23
Completion
2011-08-23

Drugs

EvaluationDrugModalityDoseRoute
Subject tigatuzumab Monoclonal antibody 8 mg/kg Intravenous
Background Carboplatin Small molecule 6 unknown Intravenous
Background Paclitaxel Small molecule 175 mg/m2 Intravenous